Prime Capital Investment Advisors LLC Buys 7,981 Shares of Thermo Fisher Scientific Inc. $TMO

Prime Capital Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,657 shares of the medical research company’s stock after acquiring an additional 7,981 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $16,324,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TMO. Guinness Atkinson Asset Management Inc raised its holdings in Thermo Fisher Scientific by 10.6% in the third quarter. Guinness Atkinson Asset Management Inc now owns 11,428 shares of the medical research company’s stock worth $5,280,000 after buying an additional 1,094 shares during the last quarter. Guinness Asset Management LTD raised its holdings in Thermo Fisher Scientific by 14.8% in the 3rd quarter. Guinness Asset Management LTD now owns 84,957 shares of the medical research company’s stock worth $39,254,000 after acquiring an additional 10,925 shares during the last quarter. MONECO Advisors LLC boosted its stake in Thermo Fisher Scientific by 2.1% during the 3rd quarter. MONECO Advisors LLC now owns 1,031 shares of the medical research company’s stock valued at $500,000 after purchasing an additional 21 shares during the last quarter. John G Ullman & Associates Inc. raised its stake in shares of Thermo Fisher Scientific by 4.1% in the third quarter. John G Ullman & Associates Inc. now owns 12,090 shares of the medical research company’s stock worth $5,864,000 after purchasing an additional 476 shares during the last quarter. Finally, Waterloo Capital L.P. lifted its holdings in shares of Thermo Fisher Scientific by 15.0% during the third quarter. Waterloo Capital L.P. now owns 2,012 shares of the medical research company’s stock valued at $976,000 after purchasing an additional 262 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMO. Evercore ISI restated an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a report on Sunday, December 7th. Argus lifted their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $633.68.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the sale, the chief operating officer directly owned 65,480 shares in the company, valued at $38,200,377.20. This represents a 32.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president directly owned 13,087 shares in the company, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 114,292 shares of company stock worth $66,518,754. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $2.80 during trading hours on Friday, hitting $539.56. The company’s stock had a trading volume of 183,312 shares, compared to its average volume of 2,562,704. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The business has a 50 day moving average price of $591.73 and a two-hundred day moving average price of $541.12. The company has a market cap of $202.72 billion, a PE ratio of 30.39, a PEG ratio of 3.26 and a beta of 0.93.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the prior year, the company posted $6.10 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.